BIODESIX INC (BDSX)

US09075X1081 - Common Stock

1.45  -0.03 (-2.03%)

Fundamental Rating

3

Taking everything into account, BDSX scores 3 out of 10 in our fundamental rating. BDSX was compared to 107 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of BDSX have multiple concerns. BDSX is valued quite expensive, but it does show an excellent growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BDSX has reported negative net income.
BDSX had a negative operating cash flow in the past year.
In the past 5 years BDSX always reported negative net income.
In the past 5 years BDSX always reported negative operating cash flow.

1.2 Ratios

BDSX has a worse Return On Assets (-42.65%) than 86.67% of its industry peers.
With a Return On Equity value of -157.30%, BDSX is not doing good in the industry: 81.90% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -42.65%
ROE -157.3%
ROIC N/A
ROA(3y)-59.93%
ROA(5y)-55.91%
ROE(3y)-558.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 77.72%, BDSX belongs to the top of the industry, outperforming 92.38% of the companies in the same industry.
In the last couple of years the Gross Margin of BDSX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.43%
GM growth 5Y-1.3%

More info and screens

3

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BDSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BDSX has been increased compared to 5 years ago.
Compared to 1 year ago, BDSX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -4.57, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
BDSX's Altman-Z score of -4.57 is on the low side compared to the rest of the industry. BDSX is outperformed by 87.62% of its industry peers.
A Debt/Equity ratio of 1.30 is on the high side and indicates that BDSX has dependencies on debt financing.
The Debt to Equity ratio of BDSX (1.30) is worse than 69.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.3
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACCN/A
WACC9.39%

2.3 Liquidity

BDSX has a Current Ratio of 3.40. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
BDSX has a Current ratio of 3.40. This is amongst the best in the industry. BDSX outperforms 89.52% of its industry peers.
BDSX has a Quick Ratio of 3.40. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
BDSX has a Quick ratio of 3.40. This is amongst the best in the industry. BDSX outperforms 89.52% of its industry peers.
Industry RankSector Rank
Current Ratio 3.4
Quick Ratio 3.4

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.67% over the past year.
BDSX shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.90%.
Measured over the past years, BDSX shows a quite strong growth in Revenue. The Revenue has been growing by 19.16% on average per year.
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)48.9%
Revenue growth 3Y2.52%
Revenue growth 5Y19.16%
Sales Q2Q%34.54%

3.2 Future

BDSX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.84% yearly.
The Revenue is expected to grow by 31.31% on average over the next years. This is a very strong growth
EPS Next Y45.34%
EPS Next 2Y28.84%
EPS Next 3Y20.84%
EPS Next 5YN/A
Revenue Next Year41.14%
Revenue Next 2Y35.68%
Revenue Next 3Y31.31%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BDSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDSX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BDSX's earnings are expected to grow with 20.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.84%
EPS Next 3Y20.84%

More info and screens

0

5. Dividend

5.1 Amount

BDSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODESIX INC

NASDAQ:BDSX (1/6/2025, 4:30:01 PM)

1.45

-0.03 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-01 2024-11-01/bmo
Earnings (Next)N/A N/A
Inst Owners30.18%
Inst Owner Change0%
Ins Owners26.05%
Ins Owner Change1.08%
Market Cap210.93M
Analysts83.33
Price Target3.16 (117.93%)
Short Float %1.32%
Short Ratio1.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.58%
Min EPS beat(2)6.41%
Max EPS beat(2)14.75%
EPS beat(4)4
Avg EPS beat(4)9.07%
Min EPS beat(4)4.24%
Max EPS beat(4)14.75%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)9
Avg EPS beat(12)2.95%
EPS beat(16)11
Avg EPS beat(16)1.65%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-4.39%
Max Revenue beat(2)8.39%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-7.86%
Max Revenue beat(4)8.39%
Revenue beat(8)3
Avg Revenue beat(8)-2.53%
Revenue beat(12)5
Avg Revenue beat(12)0.16%
Revenue beat(16)8
Avg Revenue beat(16)2.5%
PT rev (1m)0%
PT rev (3m)-0.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.22
P/FCF N/A
P/OCF N/A
P/B 7.57
P/tB 33.02
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.45
BVpS0.19
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.65%
ROE -157.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.72%
FCFM N/A
ROA(3y)-59.93%
ROA(5y)-55.91%
ROE(3y)-558.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.43%
GM growth 5Y-1.3%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 1.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 104.83%
Cap/Sales 8.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.4
Quick Ratio 3.4
Altman-Z -4.57
F-Score4
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)290.4%
Cap/Depr(5y)199.46%
Cap/Sales(3y)20.3%
Cap/Sales(5y)14.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y45.34%
EPS Next 2Y28.84%
EPS Next 3Y20.84%
EPS Next 5YN/A
Revenue 1Y (TTM)48.9%
Revenue growth 3Y2.52%
Revenue growth 5Y19.16%
Sales Q2Q%34.54%
Revenue Next Year41.14%
Revenue Next 2Y35.68%
Revenue Next 3Y31.31%
Revenue Next 5YN/A
EBIT growth 1Y28.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.01%
EBIT Next 3Y25.74%
EBIT Next 5YN/A
FCF growth 1Y-37.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.53%
OCF growth 3YN/A
OCF growth 5YN/A